IXICO plc New contract worth >$750k (5266M)
22 Septiembre 2021 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 5266M
IXICO plc
22 September 2021
IXICO plc
("IXICO" or the "Company")
First contract award from new Imaging Master Vendor Agreement
with top 5 global CRO
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, announces that it has been awarded a new
contract with a value of more than >$750k over 2 years for
advanced neuroimaging solutions by a top 5 global Clinical Research
Organization ("CRO") to support its sponsor's Phase II Alzheimer's
disease clinical trial .
Conducted across 41 investigator sites within the Unites States
and Europe, the clinical trial will enrol patients with Mild to
Moderate Alzheimer's Disease to evaluate the safety and efficacy of
a subcutaneously administered investigational product.
Following the successful completion of the CRO's independent
qualification and audit process, a Master Vendor Agreement was
executed between the CRO and IXICO in the month of August. Being
selected as a dedicated imaging vendor is expected to significantly
enhance IXICO's opportunity to partner with the CRO's client
portfolio.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"IXICO is delighted to work with our new CRO partner to support
their sponsor's Alzheimer's disease clinical trial. One of the core
elements of our commercial growth strategy has been to establish
strong relationships with select therapeutically aligned partner
CROs. This enables greater access to new biopharmaceutical clients
and accelerates the adoption of our proprietary neuroimaging
technology solutions, at scale. Our mission is to support our
clients in their tireless efforts to bring potential treatments to
patients suffering from neurological disorders. This new award
reflects the confidence that CROs and sponsors place in IXICO, as
their trusted neuroimaging partner for their pivotal CNS
studies."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFFFEIAAILFIL
(END) Dow Jones Newswires
September 22, 2021 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
